Israeli Researchers Develop Groundbreaking Blood Test to Detect Parkinson’s Disease in Early, Pre-Symptomatic Stages
By: Fern Sidman
In a major medical breakthrough, researchers from the Hebrew University of Jerusalem have developed a non-invasive blood test capable of detecting Parkinson’s disease before the onset of physical symptoms, potentially revolutionizing how the debilitating neurological disorder is diagnosed and treated. As reported by The Jewish News Syndicate (JNS) on Wednesday, the test leverages a novel approach by identifying specific RNA fragments in the bloodstream, known as tRNA-derived fragments (tRFs), which serve as early biomarkers for the disease.
The research team, led by Professor Hermona Soreq, a leading neuroscientist at Hebrew University, announced the discovery on Tuesday, calling it a “game-changing advancement” in the early detection and understanding of Parkinson’s disease. “This discovery represents a major advancement in our understanding of Parkinson’s disease and offers a simple, minimally-invasive blood test as a tool for early diagnosis,” Soreq stated, according to the JNS report.
Parkinson’s disease is a progressive neurodegenerative disorder characterized by tremors, muscle rigidity, slow movement, and impaired balance. It affects nearly one million people in the United States and millions more worldwide. Despite its prevalence, there is currently no definitive test for diagnosing Parkinson’s in its early stages. Physicians typically rely on a combination of clinical symptoms and imaging studies — methods which often detect the disease only after irreversible brain damage has already occurred.
This new blood test — described as “highly accurate, rapid, and affordable” — could shift the diagnostic timeline significantly forward, opening the door to early interventions that may delay or even prevent the progression of the disease, JNS reported.
The study was conducted in collaboration with Shaare Tzedek Medical Center in Jerusalem and two prominent UK institutions — the University of Surrey and Imperial College London. The findings were recently published in the prestigious peer-reviewed journal Nature Aging, solidifying the test’s scientific credibility and opening pathways for future clinical applications.
At the heart of the innovation is the use of tRNA-derived fragments, or tRFs, a relatively underexplored class of small RNA molecules. The JNS report indicated that these fragments are formed when transfer RNA (tRNA) — molecules traditionally known for their role in protein synthesis — are cleaved under stress or disease conditions.
Professor Soreq and her team discovered that specific tRF signatures in the blood correlate with molecular changes in the brain that are indicative of the earliest phases of Parkinson’s disease. These molecular shifts occur long before any outward signs or symptoms emerge, offering a unique opportunity for presymptomatic diagnosis.
“By focusing on tRFs, we’ve opened a new window into the molecular changes that occur in the earliest stages of the disease,” Soreq explained, as was noted in the JNS report. “This insight not only deepens our biological understanding but also paves the way for targeted therapies that can be introduced before neurological damage becomes extensive.”
As detailed in the JNS report, this breakthrough is the result of an international, interdisciplinary effort involving clinical neurologists, molecular biologists, and bioinformatics experts. The involvement of leading British institutions added critical validation through comparative studies and cross-laboratory replication of findings, enhancing the robustness and reliability of the results.
While further clinical trials will be required to bring the test to mainstream medical practice, the early data suggests a high level of sensitivity and specificity, meaning that the test not only detects Parkinson’s accurately but also minimizes false positives.
The implications of this discovery are profound. As the JNS report noted, early diagnosis could enable patients to enroll in clinical trials sooner, start neuroprotective treatments earlier, and potentially delay the disease’s progression. It also opens avenues for the development of personalized treatment strategies, tailored to the patient’s molecular profile — an exciting step toward precision medicine in neurology.
Moreover, this test could transform how at-risk individuals — such as those with family histories of Parkinson’s or known genetic mutations — are monitored, providing peace of mind or early warning that could shape lifestyle or medical decisions.
JNS reported that this breakthrough is yet another testament to Israel’s growing role as a global leader in biomedical innovation, particularly in the neurosciences. With institutions such as the Hebrew University at the forefront, the country continues to punch well above its weight in pioneering research that has tangible, life-changing impact.
As the world continues to grapple with aging populations and the rising burden of neurodegenerative diseases, the development of a simple blood test to detect Parkinson’s before symptoms manifest could be one of the most important medical advances of the decade.
In the words of Professor Soreq, as quoted by JNS: “We are optimistic that this discovery will pave the way for a future where Parkinson’s disease can be detected and treated far earlier — ultimately improving outcomes and preserving quality of life for millions around the world.”
